The effect of anticoagulant types on the in vitro analysis of clopidogrel in human plasma using liquid chromatography tandem-mass spectrometry

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The aim of this study was to optimize and validate a plasma clopidogrel analysis method using liquid chromatography tandem-mass spectrometry. Methods: Plasma samples were analyzed using a BEH C18 column (1.7 µ 100 mm×2.1 mm), the mobile phase was 0.1% formic acid in acetonitrile (30:70, v/v). The flow rate was 0.2 mL/min, with a column temperature set to 35°C, an injection volume of 5 µL, an analysis time of 4 min, and irbesartan as the internal standard. Aliquots were obtained by liquid-liquid extraction using ammonium acetate and diethyl ether. The stability and peak area ratio of the respective plasma area responses were evaluated using ANOVA. Results: No significant differences (p>0.05) were observed between anticoagulants regarding analyte stability. However, the peak area ratio showed significant differences (p<0.05) between the anticoagulants. The accuracy and precision of the analysis with citrate, heparin, and ethylenediaminetetraacetic acid (EDTA) plasma met the quality requirements, and a linear calibration curve was created with concentrations ranging from 0.02 to 5.0 ng/mL. Conclusion: The results showed that improved analysis of clopidogrel was achieved using citrate or heparin plasma compared with EDTA plasma.

Original languageEnglish
Pages (from-to)392-395
Number of pages4
JournalInternational Journal of Applied Pharmaceutics
Volume10
Issue numberSpecial Issue 1
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • Citrate
  • Clopidogrel
  • Ethylenediaminetetraacetic acid
  • Heparin
  • Liquid chromatography tandem-mass spectrometry

Fingerprint Dive into the research topics of 'The effect of anticoagulant types on the in vitro analysis of clopidogrel in human plasma using liquid chromatography tandem-mass spectrometry'. Together they form a unique fingerprint.

Cite this